Conversion therapy and R0 resection for pancreatic cancer with multiple liver metastases: a case report

胰腺癌伴多发性肝转移的转化治疗和R0切除术:病例报告

阅读:1

Abstract

BACKGROUND: Pancreatic cancer has a high degree of malignancy, poor prognosis, and short survival time. Surgical resection is the main treatment for pancreatic cancer, but the resection rate is only 20%. Liver metastases are the main reason of unresectable. The conversion therapy for pancreatic cancer with liver metastases is rare and less reported. CASE PRESENTATION: A 52-year-old male patient with pancreatic cancer and multiple liver metastases was reported. Imaging examination showed multiple low-density shadows in the liver. Laboratory tests showed elevated levels of pro-gastrin-releasing peptide and CEA. After gemcitabine combined with albumin-bound paclitaxel chemotherapy, the liver metastases disappeared and the primary pancreatic head tumor was significantly reduced. Pancreaticoduodenectomy was performed, and the patient recovered well without any other adjuvant therapy. The patient has been alive for 36 months without tumor recurrence. CONCLUSIONS: The efficacy of Gemcitabine combined with Albumin-bound paclitaxel in conversion therapy for pancreatic cancer patients with multiple liver metastases may be related to the size and duration of metastases, which needs to be further studied.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。